MIRAMAR, FL / ACCESSWIRE / January 30, 2017 / Hema Diagnostic Systems, located in Miramar, Florida, USA, a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTC PINK: GNBT), is proud to announce that Harold G. Haines, Ph.D., will expand his participation at Hema Diagnostic Systems to include project management of a new and novel multiplex assay designed for use with Sepsis. This new device has been issued the preliminary designation of RAPID 1-2-3® HEMA® SEPSIS. Dr. Haines will lead a coordinated effort involving both Hema Diagnostic Systems and Generex Biotechnology and will undertake the new responsibilities of Chief Medical Officer for Hema Diagnostic Systems while retaining his current responsibilities as Director of Clinical Affairs, a position held since 2002.
Dr. Haines has 45 plus years of executive managerial and consulting experience in the healthcare industry, with a broad background in pharmaceuticals, diagnostics, medical devices, and therapeutics and is a former tenured Professor of Pathology (with appointments in Microbiology, Immunology, Dermatology, and Obstetrics and Gynecology) at the University of Miami School of Medicine, Miami, Florida. He also established and served as Director of the Clinical Virology Laboratory at Jackson Memorial Hospital, the second largest hospital in the United States. Dr. Haines was founder and Director of the Virology Reference Laboratory at the University of Miami - School of Medicine. Both of these laboratories were among the first laboratories for the diagnosis of viral diseases in the Southeastern United States. He has founded and operated two commercial immunology and infectious disease laboratories.
According to Dr. Haines, "Sepsis is a rapidly developing inflammatory syndrome and one of the major causes of serious disability and death in hospital settings in the United States and globally. Because it can develop and intensify extremely fast in a patient, it is critical that a very rapid and accurate diagnosis be made." Dr. Haines further stated,"Hema Diagnostic Systems is developing a multiplex assay for the detection and quantitative determination of several distinct biomarkers for the diagnosis of this devastating syndrome. The results of this assay, which can be conducted either at bedside or in a central laboratory, will be available in 10-15 minutes. This multiplex assay aims to help determine the status and origin of sepsis, which is a major cause of death in hospitals, with very high predictability. This, in turn, will give the physician essential information to take the necessary treatment steps in a manner which is much more efficient and rapid than currently available tests."